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The human placenta is a poorly-understood organ, but one that is critical for proper development 35 
and growth of the fetus in-utero.  The epithelial cell type that contributes to primary placental 36 
functions is called “trophoblast,” including two main subtypes, villous and extravillous 37 
trophoblast.  Cytotrophoblast and syncytiotrophoblast comprise the villous compartment and 38 
contribute to gas and nutrient exchange, while extravillous trophoblast invade and remodel the 39 
uterine wall and vessels, in order to supply maternal blood to the growing fetus.  Abnormal 40 
differentiation of trophoblast contributes to placental dysfunction and is associated with 41 
complications of pregnancy, including preeclampsia (PE) and fetal growth restriction (FGR).  42 
This review describes what is known about the cellular organization of the placenta during both 43 
normal development and in the setting of PE/FGR.  It also explains known trophoblast lineage-44 
specific markers and pathways regulating their differentiation, and how these are altered in the 45 
setting of PE/FGR, focusing on studies which have used human placental tissues. Finally, it also 46 




Trophoblast (derived from the Greek word “tropho,” meaning to feed) is the epithelial cell in the 50 
placenta, a transient organ which plays a pivotal role in fetal growth and development during 51 
pregnancy [1]. Trophoblast are derived from trophectoderm (TE), the cells on the outer part of 52 
the blastocyst-stage embryo.  In human, the TE expands during the early post-implantation 53 
period to form a shell around the embryo, composed mostly of proliferative cytotrophoblast 54 
(CTB), the putative trophoblast “stem” cell in the placenta [1,2].  CTB subsequently differentiate 55 
down two main lineages:  in floating villi, they fuse to form syncytiotrophoblast (STB), which 56 
form the main barrier against pathogens while also serving as the gas and nutrient exchange 57 
interface, while in anchoring villi, they undergo a modified form of epithelial-to-mesenchymal 58 
transition to differentiate into invasive extravillous trophoblast (EVT) [1-3].  The latter are 59 
composed of two subtypes of cells, one of which invade deeply into the uterine wall as groups of 60 
cells, termed interstitial EVT, and another which remodel and line decidual arterioles as 61 
endovascular EVT, allowing for maternal blood flow to be established into the intervillous space 62 
[1].  Differentiation into both these lineages is important for development of a fully-functioning 63 
placenta, which can support growth of the fetus in utero.  Abnormal differentiation and function 64 
of these two lineages has been associated with pregnancy disorders, including miscarriage, 65 
preterm birth, preeclampsia (PE), and fetal growth restriction (FGR) [4,5].  This review will 66 
focus on describing trophoblast subtypes as organized within the normal placenta, and discuss 67 
how the organization of these lineages is disturbed in pregnancy complications, with a focus on 68 
placental insufficiency associated with PE and FGR.  Finally, it will also highlight gaps in 69 
knowledge, where more research is needed in understanding the relationship between abnormal 70 
trophoblast differentiation and placental function. 71 
 72 
Trophoblast lineages and their organization within the placenta 73 
 Two commonly-used markers for distinguishing villous (CTB and STB) and extravillous 74 
trophoblast (EVT) are EGFR and HLAG, respectively [6].  Early in gestation, the trophoblastic 75 
shell surrounding the embryo is composed of primary villi [1-3], whose trophoblast is 76 
highlighted by EGFR, as well as multiple layers of HLAG+ EVT, among which are abundant 77 
multinucleated giant cells (Figure 1a-b).  The origin of these giant cells has been debated: on 78 
one hand, their location within the EVT layers and increasing numbers within the uterine 79 
myometrium with increasing gestation [7] suggest they are part of this lineage. On the other 80 
hand, the predominant expression of EGFR in these cells suggests that, at least in early gestation, 81 
they are in fact of villous origin, potentially representing STB fragments, entrapped within the 82 
EVT shell (Figure 1c-d). 83 
 Later in gestation, EGFR and HLAG staining continue to represent villous and 84 
extravillous lineages, respectively.  EGFR marks the trophoblast surrounding the floating villi, 85 
but also marks the layer of trophoblast at the chorionic plate (fetal surface), while HLAG 86 
primarily highlights EVT at the basal plate (maternal surface), but also marks EVT present just 87 
below the chorionic plate and surrounding some villi within intraplacental trophoblast islands 88 
(Figure 2a-c).  Interestingly, while the majority of EVT at the basal plate express HLAG, 89 
occasional multinucleated giant cells can be seen that are double-positive for EGFR and HLAG 90 
(Figure 2d), indicating a potentially different cell-of-origin of these cells in later gestation 91 
placenta.  92 
 Within the EGFR+ villous trophoblast, CTB stem cells, visualized by TP63 93 
immunoreactivity, are abundant in early gestation, comprising a layer that is adjacent to the 94 
 4 
basement membrane (Figure 3a) [8].  Little is known about the heterogeneity of this cell layer, 95 
although single cell RNAseq analysis is beginning to shed some light on this subject [9-11].  Our 96 
own work has pointed to one marker, CDX2, which appears to highlight a subset of these villous 97 
CTB (Figure 3b).  In normal gestation, CDX2+ CTB are present mostly near the chorionic plate 98 
and disappear after first trimester [12].  The CTB layer itself starts to become discontinuous in 99 
the second trimester; by term, only 1-2 CTB can be found per terminal villus [8].  This is 100 
reflected in a decrease in PCNA staining over gestation, as CTB are the proliferative cells within 101 
the trophoblastic compartment [13]. 102 
 While there are likely many more human trophoblast subtypes than described above, few 103 
have been described or characterized, beyond mere identification with a single marker, and fewer 104 
still have been functionally defined.  Nevertheless, in the remainder of this review, we will 105 
describe changes in trophoblast differentiation and related regulatory pathways, as revealed by a 106 
combination of morphology, lineage-specific marker expression, and functional studies (where 107 
available), associated with disorders of placental insufficiency, with a focus on PE and FGR. 108 
 109 
Preeclampsia and Fetal Growth Restriction:  Clinical Synopsis 110 
Pre-eclampsia (PE) is a common pregnancy disorder that is characterized by new-onset 111 
hypertension and proteinuria in the latter half of pregnancy, and affects 5-8% of all pregnancies 112 
worldwide [14-16]. The incidence of PE in the United states has been on the rise since the 1990s, 113 
and it is currently one of the leading causes of maternal and neonatal morbidity and mortality 114 
[14]. PE is a heterogeneous disease, and can manifest itself at different gestational ages, with 115 
varying degrees of severity. Recently, a “two-stage” model has been developed to describe the 116 
underlying pathophysiology, with the first stage being deficient placentation and second stage 117 
characterized by systemic vascular inflammation [17].  PE, particularly severe early-onset PE, 118 
presenting before 34 weeks gestational age, can be accompanied by fetal growth restriction 119 
(FGR), defined as birthweight less than 10th percentile adjusted for sex and gestational age [18].  120 
However, FGR can also be present in isolation, without a simultaneous maternal syndrome [5, 121 
18,19].  While FGR can also be multifactorial, PE and isolated FGR have in common, both some 122 
clinical features, including abnormal umbilical doppler studies, as well as underlying etiologies, 123 
including defective placentation and systemic maternal vascular dysfunction [5,19].  Both PE 124 
and FGR are often associated with a small placenta at delivery, and show various combinations 125 
of villous hypermaturity, infarction, and decidual vasculopathy, on histopathologic examination 126 
[1,2].  Recent studies have used a combination of gene expression profiling and histopathology 127 
to further separate PE and FGR into unique subtypes, with the potential to identify biomarkers 128 
with improved diagnostic accuracy [20-23].  However, trophoblast lineage-specific 129 
differentiation has yet to be described in these different disease subtypes.  Below, we will 130 
describe abnormalities in both villous and extravillous trophoblast associated with PE/FGR.  131 
 132 
Abnormalities of villous trophoblast associated with PE/FGR 133 
 Normal villous trophoblast development involves regular branching of the villous tree, 134 
with fusion of underlying CTB into the overlying syncytium within these structures [2].  The 135 
process of fusion is regulated through Glial Cells Missing-1 (GCM1), a transcription factor, 136 
which is expressed in a subgroup of CTB, induces cell cycle arrest, and mediates cell-cell fusion 137 
through induction of SYNCYTIN genes [24, 25]. Downregulation of GCM1 in denuded floating 138 
villi has been shown to promote CTB proliferation and inhibit syncytial regeneration [26].  139 
Syncytialization involves induction of two fusogenic genes, SYNCYTIN 1 and 2, in human 140 
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chorionic villi, both of which were acquired from human endogenous defective retroviruses 141 
[27,28].  The syncytium undergoes significant turnover through shedding of a combination of 142 
extracellular vesicles and microparticles (sometimes referred to as trophoblast “deportation”), 143 
which, over time, with decreased fusion of underlying CTB, results in formation of nuclear 144 
aggregates, called syncytial knots [29].  The number of syncytial knots increases with increasing 145 
gestational age, and is thus a reflection of villous maturity [30].  Syncytial knots are composed 146 
primarily of condensed nuclei with transcriptionally inactive heterochromatin [31]. The presence 147 
of syncytial knots in normal term placentas is also associated with a small spike in TUNEL 148 
staining, a further reflection of placental aging [13]. 149 
PE/FGR placentas often show poor villus branching, described as “distal villous 150 
hypoplasia,” accompanied by increased numbers of syncytial knots adjusted for gestational age, 151 
consistent with “accelerated villous maturation” [32].  The latter changes were originally 152 
described by Tenney and Parker in 1940, as degenerative changes associated with “toxemia of 153 
pregnancy,” and hence are often referred to in the literature as “Tenney-Parker changes” [33].  154 
These changes are thought to arise due to more turbulent flow of maternal blood into the 155 
intervillous space of PE/FGR placentae, resulting in increased oxidative stress [34]; in fact, 156 
syncytial knots are positive for markers of oxidative damage, such as 8-oxo-deoxyguanosine 157 
[31].  The syncytial knots are also at least one source of circulating soluble VEGF receptor-1 158 
(sVEGFR-1, also known as sFlt-1), an anti-angiogenic protein, whose increased expression has 159 
been associated with, and indeed may be diagnostic for, PE [35-37]. The syncytial knots in 160 
PE/FGR also show a decrease in the anti-apoptotic BCL-2 protein and an increase in cell death, 161 
as measured by TUNEL staining [38].  The increase in cell death has been attributed to caspase-162 
independent apoptosis [39], increased levels of endoplasmic reticulum stress [40], as well as 163 
excessive autophagy [41,42].  The increase in syncytial knots and cell death leads to 164 
discontinuity of the syncytium, resulting in leakage of fetal proteins into maternal circulation 165 
[43].  It also likely leads to increased thickness (~two-fold) of the vasculosyncytial membrane, 166 
the exchange interface of chorionic villi, thus negatively affecting fetal growth [44].  Finally, at 167 
least in early-onset PE, this increase in syncytial knots and apoptosis is also associated with an 168 
increase in STB turnover/shedding, with over two-fold increase in circulating STB-derived 169 
microparticles, compared to gestational age-matched control cases [45]. 170 
At the molecular level, these alterations in STB morphology and function have been 171 
attributed to alterations in the GCM1-SYNCYTIN pathway, regulating syncytialization and STB 172 
organization. Specifically, both GCM1 and SYNCYTIN-1 proteins have been found to be 173 
reduced in PE placentae [46,47], with SYNCYTIN-1 also being mis-localized to the apical, 174 
instead of the basal, membrane in STB [47].  Hypoxia has been proposed as the potential 175 
mechanism for GCM1 downregulation, acting through suppression of the PI3K-AKT signaling 176 
pathway to activation of GSK3b, with subsequent phosphorylation of GCM1, targeting it for 177 
ubiquitination and degradation [48]. A reduction in GCM1 leads to a decrease in SYNCYTIN 178 
expression, resulting, in turn, in reduced fusion and an altered syncytium. 179 
Other functions that have been attributed to SYNCYTIN include both promotion of cell 180 
proliferation [49] and inhibition of apoptosis [39].  However, while the latter is consistent with 181 
the STB phenotype noted in PE, PE-associated alterations in villous CTB proliferation have been 182 
somewhat controversial.  Intuitively, it is easy to assume that accelerated maturation must be 183 
accompanied by a loss in CTB proliferation.  However, results of studies evaluating CTB 184 
proliferation in PE/FGR range from no differences in CTB proliferation [50,51], region-specific 185 
alterations in CTB proliferation [52], to an increase in CTB proliferation attributed to a damaged 186 
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syncytium in need of repair and regeneration [53,54]. Given the heterogeneity of PE and FGR, as 187 
recently elaborated on by genome-wide expression profiling of placental tissues associated with 188 
these complications [20-23], it is possible that distinct subclasses of these diseases have different 189 
alterations at the cellular level, including differences in CTB proliferation, depending on the 190 
underlying pathophysiology. 191 
  192 
Abnormalities of extravillous trophoblast in PE/FGR 193 
Extravillous trophoblast (EVT) differentiate from CTB precursor cells within anchoring 194 
chorionic villi at the basal plate.  This process occurs within trophoblast cell columns, where 195 
CTB gradually lose expression of EGFR and gain HLAG expression [6].  This process occurs 196 
early in gestation, in a relatively hypoxic microenvironment [55] and, in fact, is regulated by the 197 
hypoxia-inducible complex (HIF), at least in its initial transition from CTB to EVT [6].  HIF, in 198 
turn, induces expression of transcription factors ASCL2 and TEAD2, which are specifically 199 
expressed in EVT in the human placenta [6].  Hypoxia also induces NOTCH1, which inhibits 200 
expression of transcription factors involved in CTB self-renewal, including TEAD4 and TP63, 201 
represses syncytialization, and promotes proliferation and survival of EVT precursor cells [56].  202 
GCM1 is another transcription factor induced during EVT differentiation, although it does not 203 
appear to be regulated by HIF in this context [6].  Because GCM1 is also involved in STB 204 
differentiation of CTB progenitor cells [24-26], cellular context/microenvironment likely plays a 205 
key role in distinguishing which lineage is induced downstream of GCM1 expression. 206 
Aside from hypoxia/HIF, two other pathways known to be involved in EVT 207 
differentiation include epithelial-mesenchymal transition (EMT) and WNT signaling.  As the 208 
cells move distally within the column, they lose their proliferative potential and undergo what 209 
has been described as a “partial EMT,” losing some (but not all) of their epithelial markers, and 210 
gaining some mesenchymal markers [57,58].  This phenotype is accompanied by an induction of 211 
ZEB2 [57] and TEAD2 [6], as mentioned above, both of which are transcription factors known 212 
to be involved in EMT [59,60].  This process also involves a switch in cell surface integrins, 213 
from ITGA6 in CTB, to ITGA5 in cell column/immature EVT, and ITGA1 in mature EVT [61], 214 
acquiring a vascular phenotype, including induction of VE-Cadherin, VCAM-1, and PECAM 215 
[62], as well as cytoskeletal remodeling [6,57].  WNT signaling is also important for EVT 216 
differentiation, requiring to be turned off during the initial transition from CTB to EVT, but 217 
subsequently needed to be reactivated, acting through the transcription factor TCF4 to promote 218 
EVT maturation [63,64].  219 
EVTs are more difficult to evaluate, as they are left behind, for the most part, following 220 
delivery of the placenta (those in the decidua basalis).  Nevertheless, evaluation of decidual 221 
vessels present within the fetal membranes (those in the decidua parietalis) are thought to reflect 222 
the general state of maternal uterine vessels, and by inference, the functional status of 223 
endovascular EVT, for that particular pregnancy [1,2].  At the same time, evaluation of the basal 224 
plate EVT (those in the decidua basalis--at the maternal surface of the placental disc) provides at 225 
least some insight into the differentiation and function of interstitial EVT [1,2].  Combined, these 226 
evaluations have identified lesions which suggest that both PE and FGR, particularly in pre-term 227 
and severe cases, are associated with abnormalities of EVT differentiation, vascular remodeling, 228 
and invasion [1,2].  These lesions include decidual vasculopathy, characterized by 229 
hypertrophy/hyperplasia of the muscular layer of the decidual arterioles, perivascular chronic 230 
inflammation, fibrinoid necrosis, and/or infiltration by foamy macrophages [2].  The presence of 231 
decidual vasculopathy, alongside multifocal infarction, within PE/FGR placentae is highly 232 
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suggestive of a defect in endovascular EVT function, which leads to lack of proper maternal 233 
blood flow to the placenta [2].  In addition, at the basal plate, an increase in immature interstitial 234 
EVT has been confirmed by increased markers of proliferation and reduced immunostaining for 235 
human placental lactogen (HPL) [65].   236 
Additional insight into EVT differentiation and function has come from placental bed 237 
biopsies, performed post-delivery for research purposes.  These studies have pointed to limited 238 
vascular remodeling in both PE and FGR placentae, with the resulting physiologic conversion of 239 
the arteries being confined to the decidual portions of these vessels, and not extending into the 240 
myometrium [66-68].  The absence of remodeling in these biopsies has also been associated with 241 
a decrease in number of mature, HPL+ interstitial EVT [69], but with an increase in placental bed 242 
giant cells, though a specific origin for these cells has yet to be confirmed [70].  Evaluation of 243 
these biopsies by immunohistochemistry has also revealed a lack of integrin switching, as well as 244 
failure to acquire a vascular adhesion phenotype, with significantly reduced expression of VE-245 
Cadherin and VCAM-1 in endovascular and interstitial EVT, respectively [71].   246 
More recently, more specific markers for differentiated EVT subtypes have been 247 
identified and characterized in context of PE/FGR.  One example is PLAC8, which has been 248 
identified as specific to interstitial EVT [72].  PLAC8 is an actin-associated protein which 249 
promotes migration and invasion of these cells, through activation of RAC1 and CDC42 [72].  250 
However, its expression was found to be elevated in interstitial EVT of PE placentae, speculated 251 
to be a compensatory response to the shallow invasion of these cells in PE [72].  A second 252 
example is LAIR2 (Leukocyte-Associated Immunogloubin-like Receptor-2), which appears to be 253 
specific to the endovascular and vascular plug EVT [73].  LAIR2 has been noted to be decreased 254 
in chorionic villus samples of placentae associated with PE development later in pregnancy [74]; 255 
however, it is not clear whether this finding is significant, particularly if this protein is in fact 256 
specifically expressed in endovascular EVT, as CVS would be unlikely to capture this cell 257 
population.  Nevertheless, a decrease in LAIR2 in the placental bed of PE patients, if measured, 258 
may be explained by an increase in apoptosis in endovascular EVT, which has reported in 259 
context of early-onset PE accompanied by FGR [75]. Unfortunately, similar to the LAIR2 study 260 
above, many studies have used villous tissue from PE/FGR placentae to evaluate alterations in 261 
pathways involved in EVT differentiation, including EMT [76,77] and WNT signaling [78,79]. 262 
While this is understandable, given the paucity of material, particularly of placental bed biopsies, 263 
ideal for these studies, these results preclude definitive conclusions on the role of alterations of 264 
these pathways in the pathogenesis of PE/FGR.  265 
   266 
Conclusions and Gaps in Knowledge 267 
 While much has been learned about pathways regulating human trophoblast 268 
differentiation over the past ~30 years, many questions remain.  In particular, in comparison to 269 
mouse, where studies have led to the identification of numerous trophoblast subtypes in both the 270 
labyrinth and junctional zones (equivalent to villous and extravillous compartments in the human 271 
placenta) [80,81], we know very little about the heterogeneity of both CTB and EVT subtypes.  272 
Recent studies using single cell RNAseq are beginning to shed light in this area [9-11]; however, 273 
significant work remains, on identification and localization of different cell types, both within 274 
normal development of the placenta and in the setting of diseases such as PE and FGR.  Perhaps 275 
the most important point for future studies would be to first assess the expression pattern of an 276 
individual gene product within the placenta across gestation, prior to evaluation of its expression 277 
(by qPCR, western blot, or other means) using banked tissues from diseased placentae, most of 278 
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which consist of only villous portions of this organ. Alternatively, immunohistochemistry/in-situ 279 
hybridization can provide a means to evaluate cell- or region-specific expression, albeit in a less 280 
quantitative manner.  In addition, detailed molecular studies of pathways involved in EVT 281 
differentiation, specifically evaluating both interstitial and endovascular EVT in the setting of 282 
PE/FGR, are currently scant and require widely available perinatal tissue banks which include 283 
placental bed biopsies.  Finally, functional analysis of these pathways requires improved in vitro 284 
systems for studying human trophoblast differentiation, including recently-established 285 
trophoblast stem cells and organoids, as well as iPSC-based models of human placental disease 286 
[3,82,83].  With the availability of the above resources, this field is poised to significantly 287 
advance over the next few decades, accompanying development of useful biomarkers and 288 
therapies for diagnosis and treatment of placenta-based disorders of pregnancy. 289 
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Figure Legends 625 
 626 
Figure 1.  Sequential sections of an archived day-16 human embryo stained with antibodies to 627 
EGFR (A, C) or HLAG (B, D).  Formalin-fixed paraffin embedded (FFPE) tissue was sectioned 628 
and stained with a rabbit monoclonal antibody against EGFR (clone 5B7, Ventana/Roche) or a 629 
mouse monoclonal antibody against HLAG (4H84 clone, Abcam), using a Ventana Discovery 630 
Ultra automated immunostainer with standard antigen retrieval and reagents as per the 631 
manufacturer’s protocol. Note that EGFR highlights both villous trophoblast surrounding the 632 
embryonic sac (ES) and primary chorionic villi (CV), as well as trophoblast giant cells (TGC) 633 
embedded within the trophoblastic shell (S), while HLAG predominantly highlights the 634 
mononuclear trophoblast within the trophoblastic shell.  Immunostaining is shown in brown with 635 
blue (hematoxylin) counterstain.  C and D represent magnification of the trophoblastic shell area 636 
with TGC, bracketed in a rectangular area in A and B, respectively. Magnification of 40x (for A 637 
and B) and 80x (for C and D). 638 
 639 
Figure 2.  Human placenta at term double-stained with antibodies to EGFR (green) and HLAG 640 
(red), counterstained with DAPI (blue).  FFPE sections from 12 different term placentas were de-641 
paraffinized and rehydrated, and antigen retrieval was performed using heat and antigen retrieval 642 
buffer (Dako) for 20 minutes. Tissues were incubated with the same primary antibodies as used 643 
for immunohistochemistry shown in Figure 1, then visualized by Alexa 488- or Alexa 594-644 
conjugated secondary antibodies (Invitrogen) and counter-stained with the nuclear stain, DAPI. 645 
A) Chorionic plate (near the fetal surface), showing a layer of EGFR+ cytotrophoblast (CTB) 646 
immediately below the amniotic mesenchyme (AM), with HLAG+ cells emanating from the CTB 647 
layer, protruding into the intervillous space (IVS). B) Basal plate (near the maternal surface), 648 
showing EGFR+ syncytiotrophoblast covering chorionic villi (CV, top right), below which are 649 
multiple layers of mature, HLAG+ cells. C) An intraplacental trophoblast island within the 650 
placental disc, where a chorionic villus remnant (CV) gets surrounded by perivillous fibrin 651 
resulting in differentiation of CTB into HLAG+ EVT. D) An EGFR/HLAG double-positive 652 
multinucleated cell (arrow) at the basal plate, surrounded by HLAG+ EVT and unstained 653 
decidual cells.  Magnification of 80x for A-D. 654 
 655 
Figure 3.  Cytotrophoblast heterogeneity in early gestation (6-week gestational age) human 656 
placenta. FFPE sections from 5 different placentas were stained, either with antibodies against 657 
TP63 (mouse monoclonal antibody specific to p40, BC28 clone, Biocare Medical), EGFR (same 658 
antibody as in Figure 1), and CD31 (rabbit monoclonal, ab76533, Abcam) (shown in A) , or 659 
against CDX2 (rabbit monoclonal, ab76541, Abcam) (shown in B), using a Ventana Discovery 660 
Ultra automated immunostainer with standard antigen retrieval and reagents as per the 661 
manufacturer’s protocol.  A) Section showing triple staining for TP63 (brown), EGFR 662 
(magenta), and CD31 (yellow-green), counter-stained with hematoxylin (blue).  Note that TP63 663 
is uniformly expressed in the CTB layer (trophoblast layer adjacent to the villous stroma/VS).  664 
B) Section showing staining for CDX2 (brown), counter-stained with hematoxylin (blue).  Note 665 
stretches of CTB that lack CDX2 staining (yellow arrowheads). Magnification of 80x for A-B. 666 
 667 
 668 



